CI

At a glance

ClinicalIndex Comparison Record
N/ANot Yet Recruiting· 100 target
Drug / intervention
Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06672861
NCT06672861N/ANot Yet Recruiting

Development and Validation of the Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) in Patients With Postural Orthostatic Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Other Disorders of Cardiac Dysautonomia

Kansas City Heart Rhythm Research Foundation·interventional·Posted Nov 4, 2024·Updated Aug 28, 2025

In Brief

A clinical study evaluating Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) for Cardiac Dysautonomia. Not yet recruiting, targeting 100 participants across 3 sites.

Detailed Summary

Main aim will be to compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ANot Yet Recruiting
20252026
First PostedNov 4, 2024
Enrollment StartJan 1, 2026
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 7 monthsPosted 1.7 years agoPrimary completion in 1 month

Interventions

Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ)other

To compare in patients with cardiac dysautonomia, newly developed disease specific questionnaire to established generalized SF-36 and EQ-5d questionnaires, as there are no disease specific questionnaires for comparison. These novel and established questionnaires will then be compared among groups who have relatively stable disease or stable symptoms with patients who will be expected to have a change in symptoms and QoL.